Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.

TitleIndoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
Publication TypeJournal Article
Year of Publication2018
JournalOncotarget
Volume9
Issue34
Pagination23482-23493
Date Published2018 May 4
AbstractIndoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme with immunomodulatory properties that has emerged as a potential immunotherapeutic target in human cancer. However, the role, expression pattern, and relevance of IDO1 in esophageal cancer (EC) are poorly understood. Here, we utilize gene expression analysis of the cancer genome atlas (TCGA) and immunohistochemistry (IHC) to better understand the role and prognostic significance of IDO1 in EC.
URLhttp://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=25235
DOI10.18632/oncotarget.25235
PubMed Linkhttp://www.ncbi.nlm.nih.gov/pubmed/29805749?dopt=Abstract
Short TitleOncotarget